Core Insights - The "Silkway Beijing 2025 China-Finland Youth Innovation Industry Matching Event" was held in Zhongguancun, showcasing the results of Sino-Finnish youth sci-tech cooperation and promoting deep integration in industry, technology, and ecology [1][2] - The establishment of the InnoHub (Beijing) innovation base by the Aalto Innovation Association and Zhongguancun Science City Company aims to provide long-term support for bilateral exchanges in innovation, industry, and talent [1] - A memorandum of understanding was signed to establish a stable partnership in innovation incubation, technology transfer, and talent exchange, injecting continuous momentum into Sino-Finnish sci-tech cooperation [1][2] Industry Collaboration - Six Finnish companies and three Chinese companies showcased their technological achievements and shared cooperation intentions, including collaborations in medical technology and smart automotive platforms [2] - The Silkway Beijing 2025 acceleration camp has actively linked Sino-Finnish sci-tech resources since its launch on October 14, hosting various events to lay a solid foundation for future cooperation [2] - The collaboration with the Aalto Innovation Association highlights the broad space for cooperation in robotics and healthcare, expanding new channels for innovation synergy and youth exchanges [3] Future Directions - The Silkway Beijing 2025 acceleration camp will continue to expand industrial cooperation and result implementation, advancing Sino-Finnish youth innovation collaboration to deeper levels [2] - Zhongguancun Science City aims to assist more enterprises in Haidian to integrate into the global sci-tech ecosystem with an open approach, depicting a new vision of the "Silk Road" in the new era [2]

Group 1 - The "2025 China-Korea Innovation Industry Technology Cooperation Matching Conference" was held in Nanjing, showcasing 13 high-quality technology innovation projects from South Korea, focusing on technology cooperation and results implementation [1][2] - The projects primarily cover three key areas: biomedicine, artificial intelligence, and energy dual carbon [1][2] - The KIST Innovation Center aims to foster collaboration with local top universities in Jiangsu to expand its market presence in China [2] Group 2 - The biomedicine industry is a strategic emerging industry prioritized for development in Nanjing, with nearly half of the showcased projects focusing on this sector, including AI-assisted drug development and smart rehabilitation devices [2][3] - A significant highlight of the conference was the signing of cooperation agreements between the China-Japan-Korea Innovation Cooperation Center, the Yangtze River Delta National Technology Innovation Center, and KIST Innovation [2] - The Yangtze River Delta National Technology Innovation Center has established formal partnerships with 93 renowned universities and international organizations, and collaborates with 40 multinational companies to enhance innovation ecosystems [3] Group 3 - Following the roadshow, 10 Chinese companies engaged in in-depth discussions with Korean project teams on topics such as industrial upgrades and clinical data sharing [4] - Korean companies expressed a strong interest in the technological innovations presented, recognizing significant opportunities for collaboration in technology development and product cooperation [4] - The China-Japan-Korea Innovation Cooperation Center is focused on strengthening practical cooperation among research institutions, universities, and enterprises in the three countries, promoting the transformation of scientific and technological achievements [4]

Group 1 - A new company, Yixing Science and Technology Innovation Industry Investment Co., Ltd., was established on October 28 [1] - The legal representative of the company is Zhang Xiaogang [1] - The registered capital of the company is 3 billion RMB [1] - The company's business scope includes investment activities, equity investment, and venture capital using its own funds [1] - The company is wholly owned by the Yixing Municipal Government's State-owned Assets Supervision and Administration Office [1]

Core Insights - The establishment of the Central Enterprise Strategic New Industry Development Fund is a key initiative to support the development of strategic emerging industries in China [1][2] - The fund aims to enhance the core functions and competitiveness of state-owned enterprises (SOEs) by addressing industrial weaknesses and focusing on cutting-edge innovations [1][2] Fund Details - The fund, initiated by the State-owned Assets Supervision and Administration Commission (SASAC), has an initial scale of 51 billion yuan, with China Reform Holdings contributing approximately 15 billion yuan [1] - Participating contributors include major companies such as China Mobile, Sinopec, and China National Petroleum, among others [1] Strategic Focus - The fund will prioritize support for industries such as artificial intelligence, aerospace, high-end equipment, quantum technology, future energy, future information, and future manufacturing [1][2] - The SASAC emphasizes that the fund will serve national strategic needs and promote the enhancement of the industrial chain [2] Development Goals - Beijing's government plans to strengthen innovation capabilities and support systems to facilitate the fund's development in the city [4] - The fund aims to create a strategic innovation ecosystem that integrates technology innovation, capital operation, and industrial empowerment, generating a multiplier effect [4] Historical Context - China Reform Holdings was designated as a pilot for state capital operation in early 2016 and transitioned to a deepening reform phase in December 2022 [5] - As of October 28, 2023, the China Reform Holdings has invested in over 320 projects, totaling more than 120 billion yuan [5]

Core Insights - The report highlights concerns regarding the independence of the Federal Reserve, particularly in light of political pressures, which may impact the macroeconomic narrative and the valuation of the US dollar [2] - The report provides a detailed analysis of various companies, focusing on their financial performance and strategic initiatives [3][4][5][6][7][8][10][11][12][17][19][20][22][24][25][26][27][28][30][31] Company Summaries - **Lihigh Food (300973 CH, Buy)**: The company reported revenue of 3.14 billion and net profit of 250 million for the first three quarters of 2025, showing year-on-year growth of 15.7% and 22.0% respectively. Despite pressure on gross margins due to rising palm oil prices, effective cost control has helped maintain profitability [3] - **Red Flag Chain (002697 CH, Accumulate)**: The company achieved revenue of 7.11 billion in the first three quarters of 2025, a year-on-year decrease of 8.5%. The net profit was 383 million, down 1.9% year-on-year. The company is focusing on internal management and cost reduction to improve profitability [4] - **Kanglong Chemical (300759 CH, Buy)**: The company reported revenue of 10.086 billion and adjusted net profit of 1.227 billion for the first three quarters of 2025, reflecting year-on-year growth of 14.4% and 10.8% respectively. The company has raised its revenue growth guidance for 2025 from 10-15% to 12-16% [5] - **Zhou Dasheng (002867 CH, Buy)**: The company reported revenue of 6.772 billion for the first three quarters of 2025, a decline of 37.3% year-on-year, while net profit increased by 3.1%. The growth in net profit is attributed to a higher proportion of high-margin products [6] - **Aimeike (300896 CH, Buy)**: The company reported revenue of 566 million in Q3 2025, down 21.3% year-on-year, with a net profit of 304 million, down 34.6%. The company is focusing on expanding its product pipeline and international market presence [7] - **Leixin Technology (688018 CH, Accumulate)**: The company achieved revenue of 1.912 billion in the first three quarters of 2025, a year-on-year increase of 30.97%. Despite a slight decline in Q3 revenue, the company is expanding its market presence in high-performance SoC [8] - **Zhongke Chuangda (300496 CH, Buy)**: The company reported revenue of 5.148 billion for the first three quarters of 2025, reflecting a year-on-year increase of 39.34%. The growth is driven by the AIOT sector [9] - **Yihua (301029 CH, Buy)**: The company reported revenue of 736 million in Q3 2025, up 17.52% year-on-year, with a net profit of 136 million, up 28.59%. The growth is attributed to the continued demand in lithium battery and automotive sectors [10] - **Huazhi Technology (688281 CH, Buy)**: The company reported revenue of 285 million in Q3 2025, a year-on-year increase of 12.85%. The company is focusing on its leading position in stealth materials [11] - **Chengdu Bank (601838 CH, Buy)**: The bank reported a net profit of 5.0% and revenue growth of 3.0% for the first nine months of 2025, indicating stable performance despite non-interest income fluctuations [12] - **Yun Tianhua (600096 CH, Buy)**: The company reported revenue of 12.6 billion in Q3 2025, a year-on-year decrease of 14%, but net profit increased by 24%. The company benefits from strong export demand for phosphate products [13] - **Funi Co., Ltd. (600483 CH, Buy)**: The company reported revenue of 3.666 billion in Q3 2025, down 4.04% year-on-year, but net profit increased by 11.53%. The company is focusing on its project reserves and renewable energy contributions [14] - **Hongcheng Environment (600461 CH, Buy)**: The company reported revenue of 1.738 billion in Q3 2025, up 2.41% year-on-year, with net profit of 324 million, reflecting stable operational performance [15] - **Op Lighting (603515 CH, Accumulate)**: The company reported revenue of 1.692 billion in Q3 2025, down 0.59% year-on-year, with net profit of 208 million, down 12.22%. The company is expected to recover as the housing market stabilizes [16] Industry Insights - The macroeconomic environment is influenced by political pressures on the Federal Reserve, which may affect market confidence and asset valuations [2] - The food and beverage sector is experiencing mixed performance, with some companies managing to maintain profitability through cost control and strategic initiatives [3][4][5][6] - The healthcare and pharmaceutical sectors are showing resilience, with companies reporting steady revenue growth and improved cash flow [7][8][9] - The technology sector, particularly in AI and IoT, is witnessing significant growth, driven by increased demand for advanced solutions [10][11][12] - The banking sector is showing stable performance, with banks managing to maintain profitability despite fluctuations in non-interest income [13][14] - The energy sector is focusing on renewable energy projects, with companies looking to expand their project reserves and improve operational efficiency [15][16]

Core Points - The company has disclosed its third-quarter report for 2025, ensuring the accuracy and completeness of the information presented [1][6][35] - The board of directors held a meeting on October 28, 2025, to review and approve various proposals, including the third-quarter report and amendments to the company's articles of association [3][5][10] - The company plans to hold its first extraordinary general meeting of 2025 on November 13, 2025, to discuss several key proposals [28][41] Group 1: Board Meeting Details - The board meeting was conducted with all seven directors present, and the meeting adhered to legal and procedural requirements [3][4][9] - The board approved the third-quarter report, confirming that it reflects the company's actual situation without any misleading statements [6][35] - The board also approved amendments to the company's articles of association to enhance governance and operational standards [10][11] Group 2: Governance and Structural Changes - The company will add one employee representative director, increasing the board size to eight members, including three independent directors [10][11] - Various governance documents and rules were revised and approved, including the rules for the board of directors and the audit committee [12][13][14][15][16] - The monitoring committee will cease to exist as its functions will be transferred to the audit committee, following the new Company Law [38][39] Group 3: Financial and Operational Plans - The company has approved a total fixed asset investment budget of 756.7 million yuan for the fifth phase of its R&D production base in Pingshan, expected to be completed by the end of 2028 [26][27] - The company will utilize its own funds for the project, which includes construction costs for facilities and equipment [26] Group 4: Upcoming Meetings and Proposals - The first extraordinary general meeting of 2025 is scheduled for November 13, 2025, to discuss the approved proposals from the board meeting [28][41] - The board has proposed the election of a new independent director to fill the vacancy left by the resignation of an existing independent director [22][24]

Core Viewpoint - The company announced the resignation of independent director Zhang Min due to personal reasons, along with her positions in various committees [1] Summary by Categories Company Governance - Zhang Min has submitted her written resignation from the company's fifth board of directors [1] - Following her resignation, she will no longer hold any positions within the company [1] Committees - Zhang Min will also resign from her roles as the chairperson of the Audit Committee, a member of the Compensation and Assessment Committee, and a member of the Nomination Committee [1]

信息披露暂缓与豁免管理制度 深圳市新产业生物医学工程股份有限公司 信息披露暂缓与豁免管理制度 （2025 年 10 月 28 日经第五届董事会第五次会议审议通过） 第一章 总则 第一条 为规范深圳市新产业生物医学工程股份有限公司（以下简称"公司"） 信息披露暂缓与豁免行为，确保公司及相关信息披露义务人依法合规履行信息披 露义务，保护投资者的权益，根据《中华人民共和国证券法》《上市公司信息披 露暂缓与豁免管理规定》《深圳证券交易所创业板股票上市规则》（以下简称"《股 票上市规则》"）《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》（以下简称"《规范运作指引》"）等法律法规及《公司章程》 《信息披露管理制度》等公司制度的有关规定，制定本制度。 第二条 公司按照《股票上市规则》《规范运作指引》及深圳证券交易所（以 下简称"深交所"）其他相关业务规则的规定，办理信息披露暂缓、豁免业务的， 适用本制度。 第二章 适用情形 第三条 公司和其他信息披露义务人有确实充分的证据证明拟披露的信息涉 及国家秘密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以下 统称"国家秘密"），依法豁免披露 ...

董事、高级管理人员离职管理制度 深圳市新产业生物医学工程股份有限公司 第一条 为规范深圳市新产业生物医学工程股份有限公司（以下简称"公司"） 董事、高级管理人员的离职程序，明确董事、高级管理人员离职后的责任义务， 保障公司治理结构稳定，保护公司和股东的合法权益，根据《中华人民共和国公 司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第2号——创业板市公司规范运作》等相关律法规及《公司章程》，结合 公司实际情况，制定本制度。 第二条本制度适用于公司全体董事（含独立董事）及高级管理人员因任期届 满、辞任、被解除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条公司董事和高级管理人员可以在任期届满以前辞任，并应向公司董事会 提交书面离职报告，说明离职原因、任职期间的履职情况，移交所承担的工作。 第四条 除下列情形外，董事的辞职自辞职报告送达董事会时生效： (一) 董事辞任导致董事会成员低于法定最低人数； 董事、高级管理人员离职管理制度 （2025 年 10 月 28 日经第五届董事会第五次会议审议通过） 第一章 总则 董事、高级管理人员离职管理制度 在辞职报告生效之前，拟辞职 ...

内部审计管理制度 深圳市新产业生物医学工程股份有限公司 内部审计管理制度 （2025 年 10 月 28 日经第五届董事会第五次会议审议通过） 第一章 总则 第一条 为规范深圳市新产业生物医学工程股份有限公司（以下简称"公司"） 内部审计工作，提高内部审计工作质量，保护投资者合法权益，依据《中华人民 共和国审计法》《审计署关于内部审计工作的规定》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》、国家五部委（财政部、审计署、证监会、银监会、保监会）关于 《企业内部控制基本规范》和《企业内部控制应用指引》、《企业内部控制评价 指引》以及《企业内部控制审计指引》等有关法律、法规、规章和规范性文件的 规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司各内部机构与公司治理、财务报告和信息披露事 务相关的所有业务环节所进行的内部审计工作。 第三条 本制度所称内部审计，是指由公司内部机构或人员依据国家有关法 律法规、财务会计制度和公司内部管理规定，通过系统化和规范化的方法，对其 内部控制和风险管理的有效性、财务信息的真实性和完整性以及经营活动的效 ...